• Till Hamann, Katharina Kamm, Peter Kropp, Florian Rimmele, and Tim Patrick Jürgens.
• Klinik und Poliklinik für Neurologie, Kopfschmerzzentrum Nord-Ost, Universitätsmedizin Rostock, Gehlsheimer Straße 20, 18147, Rostock, Deutschland. till.hamann@med.uni-rostock.de.
• Schmerz. 2020 Dec 1; 34 (6): 476-485.

BackgroundMigraine is a frequently underdiagnosed disease that is associated with a high burden on affected patients. There are a variety of prophylactic treatment options available, that have been expanded with the introduction of the CGRP-(receptor-)antibodies.ObjectivesStatus of pharmacologic and nonpharmacologic preventive treatment in migraine therapy.MethodsAnalysis and evaluation of internationally published articles concerning preventive treatment of episodic and chronic migraine.ResultsThere are many approved medications for migraine prophylaxis with different evidence. The possibilities were further expanded with CGRP antibodies. Comparative studies of the new antibodies with previous prophylactic drugs have not yet been published, so it's unclear whether the antibodies are therapeutically superior. What should be emphasized is their rapid onset of action and their good tolerance. Basically, an individual choice of prophylaxis, which is based on affectedness, comorbidities and comedication, makes sense. In addition, a combination with nondrug measures is always mandatory.ConclusionsA variety of medicinal and non-medicinal measures are available for the treatment of migraine, which should be used multimodally.

14 keywords...

hide…